In addition to industry giants such as Lilly and Novo Nordisk, some smaller and less well-known biotech companies also deserve investors’ attention due to their greater potential for growth, and Structure Therapeutics (GPCR) is one of them. The company is about to reach several key catalysts that could drive its stock price upward over a period of time.
Pharmaceutical companies are employing various strategies to enter the weight management market, and Structure Therapeutics is focused on developing oral medications. Its growth potential primarily stems from two aspects: first, although currently dominant injectable weight-loss drugs are highly effective, many patients still prefer daily oral pills over weekly injections; second, oral medications are less costly in terms of production, storage, and distribution. If their efficacy is comparable or even superior, they would possess significant commercial advantages. However, all of this depends on whether the company can achieve solid clinical trial results.
The company’s core product in development, aleniglipron, is an oral GLP-1 receptor agonist intended for the treatment of obesity. Based on its current strategy, Structure Therapeutics aims to develop aleniglipron into a multi-purpose weight-loss drug to overcome the limitations of current injectable formulations, such as issues related to dosage form and muscle loss. If the Phase II data yields positive results, the company’s stock price is likely to rise rapidly. Should subsequent clinical progress proceed smoothly, this momentum could continue into 2026.
Oral weight management drugs have long been highly anticipated by the market. For instance, Lilly’s orforglipron achieved a 12.4% weight loss over 72 weeks at the highest dose in Phase III studies, while Viking Therapeutics’ oral candidate VK2735 achieved a 12.2% weight loss in 13 weeks but suffered a high dropout rate due to side effects, leading to a sharp decline in its stock price. This also indicates that Structure Therapeutics’ ACCESS study must not only demonstrate significant efficacy—such as achieving double-digit weight loss percentages in the early stages—but also maintain good safety and tolerability, avoiding trial disruptions due to adverse effects.
Success will directly determine the trajectory of Structure Therapeutics’ stock price: if the results are positive, the stock price could rise significantly; if expectations are not met, it could face a substantial decline. It is worth noting that Structure Therapeutics also has other drug candidates in Phase I and Phase II stages, along with relatively ample cash flow. As of the second quarter, its total cash, cash equivalents, and short-term investments amounted to $786.5 million, which is expected to sustain operations until 2027. If research and development proceed smoothly, the company is likely to seek additional funding through a secondary stock offering.
Despite its considerable potential, investing in Structure Therapeutics remains a high-risk endeavor. It is suitable for investors who can tolerate significant volatility to consider cautiously and allocate moderately, while investors with average risk tolerance should adopt a wait-and-see approach.
